NOVEL COMBINATION CANCER THERAPIES

摘要

The invention describes methods of treating cancer in which a therapeutically-effective amount of a 17a-hydroxylase/C17,20-lyase inhibitor is administered to a subject in need thereof, including a subject with a refractory cancer and/or a subject currently undergoing another cancer treatment, wherein the 17a-hydroxylase/C17,20-lyase inhibitor is administered in combination with a therapeutically-effective amount of at least one additional therapeutic agent, including, but not limited to, another anti-cancer agent or a steroid.